Conditions Magazine Patients Safety 
Alchimia
MARCH 16, 2016
Once the disease starts affecting the person, life expectancy greatly depends on patients (from 3 to 20 years), with an average of 8,5 years. Patient associations estimate that we’ll have around 1,5 million people suffering from Alzheimer in Spain by 2050. Cannabis patient. Source: Spanish Society of Neurology ).
Cannabis Law Report
NOVEMBER 24, 2021
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Freedom Leaf
OCTOBER 15, 2018
On July 23, the World Health Organization’s Expert Committee on Drug Dependence stated that “no public health problems have been associated with CBD use” and that “CBD has been found to be generally well tolerated with a good safety profile.” If you enjoyed this Freedom Leaf article, subscribe to the magazine today!
Cannabis Law Report
AUGUST 4, 2021
Eurofins’ Clinical Diagnostics business in North America continues to innovate new testing methods to expand its services for transplant patients. The Environment Testing business in North America was impacted by restrictions around sample collection and adverse weather conditions.
Cannabis Law Report
AUGUST 12, 2019
The Medics prescribe the patient’s recommendation for medical cannabis products that can be purchased by the patient (1) in various delivery routes : oral, inhalation, tinctures, oils, topicals, smokable; and (2) in various products and strains, depending on the particular dispensary. Almut Winterstein, Ph.D.,
Cannabis Law Report
SEPTEMBER 23, 2019
Marijuana and related substance misuse are complex issues impacting family medicine, patient health, and public health. Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. Executive Summary. Relevant AAFP Policy. Call to Action.
Cannabis Law Report
JULY 21, 2022
Patient safety concerns uncovered during an ongoing federal review have led to the suspension of one of two clinical trials for MDMA-assisted psychotherapy currently underway in Canada. A spokesperson told CBC in an email that the study was put on hold “due to concerns for participant safety.” CBC Canada.
Expert insights. Personalized for you.
76 
Let's personalize your content